Evidence map›Paper›PMID 39729390›Full record

ArticleInternational journal of cancer2025

Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.

Maria Kouvaraki, Ioannis Zerdes, Emmanouil G Sifakis, Michail Sarafidis, Alexios Matikas, Evangelos Tzoras, Una Kjällquist, Konstantina Stathopoulou, John Lövrot, Amjad Alkodsi and 8 more

Registry-linked trialAbstract read
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01433614 (Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01433614 phase3completednot on this map

Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study

TypeinterventionalSponsorThomas HatschekRan2002 to 2013Enrolled304ConditionsMetastatic Breast CancerArmsEpirubicin, Paclitaxel, Capecitabine
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Maria KouvarakiDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-5819-4659
Ioannis ZerdesDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Emmanouil G SifakisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Michail SarafidisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Alexios MatikasDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-4122-9624
Evangelos TzorasDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Una KjällquistDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Konstantina StathopoulouDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
John LövrotDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Amjad AlkodsiApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
Johan HartmanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Christos SotiriouBreast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Francois RichardLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Thomas HatschekDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Nikolas HeroldChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
Jonas BerghDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
George Z RassidakisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Theodoros FoukakisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Funding

Cancerfonden 1494 PjCancerfonden CAN 2018/846Cancerföreningen i Stockholm (the Cancer Society in Stockholm) 174113Iris, Stig och Gerry Castenbäcks foundationKnut and Alice Wallenberg Foundation fundStockholms Läns Landsting (Stockholm County Council) FoUI-974942Swedish Society of Oncology postdoctoral grant FoUI-977295Vetenskapsrådet 2020-01184Wellcome Trust 211143
6 · The paper itself

Abstract

Sterile alpha motif and HD domain-containing protein 1 (SAMHD1) is a dNTP hydrolase important for intracellular dNTP homeostasis and serves as tumor suppressor and modulator of antimetabolite efficacy in cancer, though largely unexplored in breast cancer (BC). A cohort of patients with early BC (n = 564) with available gene expression data (GEP) was used. SAMHD1 protein expression was assessed by immunohistochemistry performed on tissue microarrays. A large pooled transcriptomic dataset was used for validation (n = 2402). GEP data from the metastatic TEX randomized phase III trial (NCT01433614) were used for SAMHD1 predictive evaluation in response to capecitabine. SAMHD1 protein and mRNA levels were higher in HER2-enriched/HER2+ and basal-like (BL)/ER-/HER2- BC. Both SAMHD1 gene and protein expression were independently associated with favorable outcomes in BL tumors. In the pooled dataset, SAMHD1 gene expression was independently associated with favorable disease-free survival in the entire population and within the BL and HER2-enriched molecular subtypes. In metastatic BC, SAMHD1 mRNA levels were higher in responders receiving capecitabine. In conclusion SAMHD1 gene and protein expression represent promising prognostic biomarkers in BL early BC.

Indexed as

Biomarkers, TumorBreast NeoplasmsSAM Domain and HD Domain-Containing Protein 1AdultAgedCapecitabineDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisBiomarkers, TumorCapecitabineSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanbasal‐likebiomarkerbreast cancerprognosisSAMHD1STING

Identifiers

PMID39729390
PMCPMC11826144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.